Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

Journal of Clinical Investigation

Volumn 111, Issue 9, 2003, Pages 1347-1356

  Mingozzi, Federico ^a   Liu, Yi Lin ^a   Dobrzynski, Eric ^a   Kaufhold, Antje ^a   Liu, Jian Hua ^a   Wang, YuQin ^a   Arruda, Valder R ^a   High, Katherine A ^a   Herzog, Roland W ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9;

ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE TRANSFER; GENETIC DISORDER; HEMOPHILIA B; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INBRED STRAIN; INHIBITION KINETICS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRAIN DIFFERENCE; TH1 CELL; TRANSGENICS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIGENS, CD95; DEPENDOVIRUS; FACTOR IX; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-4; LIVER; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; PROMOTER REGIONS (GENETICS); RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0037988905     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200316887     Document Type: Article

References (47)

1. Giannelli, F., and Green, P.M. 1996. The molecular basis of hemophilia A and B. Baillieres Clin. Haematol. 9:211-228.
2. Ljung, R., Petrini, P., Tengborn, L., and Sjoerin, E. 2001. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Brit. J. Haematol. 113:81-86.
3. Chao, H., et al. 1999. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther. 6:1695-1704.
4. Herzog, R.W., et al. 1999. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5:56-63.
5. Snyder, R.O., et al. 1999. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5:64-70.
6. Wang, L., Takabe, K., Bidlingmaier, S.M., Ill, C.R., and Verma, I.M. 1999. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. Natl. Acad. Sci. U. S. A. 96:3906-3910.
7. Carter, P.J., and Samulski, R.J. 2000. Adeno-associated viral vectors as gene delivery vehicles. Int J. Mol. Med. 6:17-27.
8. Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood. In press.
9. Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96(Suppl.):798a-799a.
10. Herzog, R.W., Mount, J.D., Arruda, V.R., High, K.A., and Lothrop, C.D.J. 2001. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther. 4:192-200.
11. Fields, P.A., et al. 2001. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in context of a large factor IX gene deletion. Mol. Ther. 4:201-210.
12. Herzog, R.W., et al. 2002. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13:1281-1291.
13. Connelly, S., et al. 1998. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 91:3273-3281.
14. Kung, J., et al. 1998. Human F.IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 91:784-790.
15. Fields, P., et al. 2001. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 8:354-361.
16. Connelly, S., Gardner, J.M., Lyons, R.M., McClelland, A., and Kaleko, M. 1996. Sustained expression of therapeutic levels of human factor VIII in mice. Blood. 87:4671-4677.
17. Pastore, L., et al. 1999. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum. Gene. Ther. 10:1773-1781.
18. Nathwani, A.C., et al. 2001. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 97:1258-1265.
19. Mount, J.D., et al. 2002. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 99:2670-2676.
20. Nakai, H., et al. 1998. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 91:4600-4607.
21. Le, M., et al. 1997. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood. 89:1254-1259.
22. Nakai, H., et al. 2001. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75:6969-6976.
23. Matsushita, T., et al. 1998. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5:938-945.
24. Mingozzi, F., et al. 2002. Improved hepatic gene transfer using an adeno-associated virus serotype 5 vector. J. Virol. 76:10497-10502.
25. Lin, H.F., Maeda, N., Smithies, O., Straight, D.L., and Stafford, D.W. 1997. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962-3966.
26. Fields, P.A., et al. 2000. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX. Mol. Ther. 1:225-235.
27. Qian, J., Collins, M., Sharpe, A.H., and Hoye, L.W. 2000. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 95:1324-1329.
28. Ke, Y., Pearce, K., Lake, J.P., Ziegler, H.K., and Kapp, J.A. 1997. Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. J. Immunol. 158:3610-3618.
29. Miller, A., Lider, O., and Weiner, H.L. 1991. Antigen-driven bystander suppression after oral administration of antigens. J. Exp. Med. 174:791-798.
30. Anand, V., et al. 2002. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol. Ther. 5:125-132.
31. Weiner, H.L. 2001. Induction and mechanism of action of transforming growth factor-beta-secreting. Th3 regulatory cells. Immunol. Rev. 182:207-214.
32. Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S., and Levings, M.K. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68-79.
33. Liu, Y.J. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 106:259-262.
34. Knolle, P.A., et al. 1999. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterol. 116:1428-1440.
35. 2002. Cabo II: immunology and gene therapy. Mol. Ther. 5:486-491.
36. Chao, H., and Walsh, C.E. 2001. Induction of tolerance to human factor VIII in mice. Blood. 97:3311-3312.
37. Bagley, J., Tian, C., Sachs, D.H., and Iacomini, J. 2002. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood. 99:4394-4399.
38. Georgantas, R.W., III, Leong, K.W., and August, J.T. 2000. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum. Gene Ther. 11:851-858.
39. Tran, N.D., et al. 2001. Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. Blood. 97:3417-3423.
40. Knolle, P.A., and Gerken, G. 2000. Local control of the immune response in the liver. Immunol. Rev. 174:21-34.
41. Vemuru, R.P., et al. 1992. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation - implications for gene therapy. FASEB J. 6:2836-2842.
42. Limmer, A., et al. 2000. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 6:1348-1354.
43. Snyder, R.O., et al. 1997. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16:270-276.
44. Jooss, K., Yang, Y., Fisher, K.J., and Wilson, J.M. 1998. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72:4212-4223.
45. Bristol, J.A., et al. 2001. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion. Hum. Gene Ther. 12:1651-1661.
46. Chao, H., Mao, L., Bruce, A.T., and Walsh, C.E. 2000. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 95:1594-1599.
47. Zaiss, A.K., et al. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.